Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Phase 3, two-stage, randomized trials of mezigdomide-based regimens versus standard regimens in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1 (MeziVd vs PVd) and SUCCESSOR-2 (MeziKd vs Kd)
Meletios A. Dimopoulos, MD
Professor and Chairman of the Department of Clinical Therapeutics
National and Kapodistrian University of Athens, Greece